The urokinase receptor (uPAR, CD87) as a target for tumor therapy: uPA-silica particles (SP-uPA) as a new tool for assessing synthetic peptides to interfere with uPA/uPA-receptor interaction.
Recent Results Cancer Res
2003
162
3-14
[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]
Zentralbl Gynakol
2003
125
9
362-7
Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Recent Results Cancer Res
2003
162
89-100
[Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]
MMW Fortschr Med
2003
145
24
34-6, 38
[Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)]
MMW Fortschr Med
2003
145
3-4
8, 10
[Counselling, genetic testing and prevention in women with hereditary breast- and ovarian cancer. Interdisciplinary recommendations of the consortium "Hereditary Breast- and Ovarian Cancer" of the German Cancer AiD]
Zentralbl Gynakol
2003
125
12
494-506
[Chemoprevention of breast cancer: a literature review and report on the current status in Germany]
Zentralbl Gynakol
2003
125
9
338-45
Reduction or elimination of postoperative pain medication after mastectomy through use of a temporarily placed local anesthetic pump vs. control group.
Zentralbl Gynakol
2003
125
1
17-22